D. Boral Capital Reiterates "Buy" Rating for Quince Therapeutics (NASDAQ:QNCX)

D. Boral Capital reiterated their buy rating on shares of Quince Therapeutics (NASDAQ:QNCX - Free Report) in a report issued on Thursday morning,Benzinga reports. The firm currently has a $4.00 target price on the stock.

A number of other research analysts have also weighed in on the stock. Oppenheimer began coverage on shares of Quince Therapeutics in a research note on Monday, March 24th. They issued an "outperform" rating and a $10.00 price objective on the stock. Wall Street Zen lowered shares of Quince Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. One research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, Quince Therapeutics presently has an average rating of "Buy" and a consensus price target of $8.00.

Quince Therapeutics Trading Up 3.3%

Shares of NASDAQ:QNCX traded up $0.06 during trading on Thursday, reaching $1.89. The stock had a trading volume of 159,826 shares, compared to its average volume of 316,655. The firm's fifty day moving average is $1.33 and its 200 day moving average is $1.36. The company has a debt-to-equity ratio of 0.82, a quick ratio of 4.05 and a current ratio of 4.05. Quince Therapeutics has a 52 week low of $0.51 and a 52 week high of $2.45. The stock has a market cap of $85.94 million, a price-to-earnings ratio of -1.36 and a beta of 0.96.

Quince Therapeutics (NASDAQ:QNCX - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.10). As a group, equities analysts forecast that Quince Therapeutics will post -1.21 EPS for the current fiscal year.

Hedge Funds Weigh In On Quince Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC raised its stake in shares of Quince Therapeutics by 48.4% during the first quarter. Virtu Financial LLC now owns 43,332 shares of the company's stock worth $58,000 after acquiring an additional 14,128 shares in the last quarter. Northern Trust Corp boosted its stake in Quince Therapeutics by 48.5% in the 4th quarter. Northern Trust Corp now owns 50,524 shares of the company's stock worth $94,000 after purchasing an additional 16,501 shares in the last quarter. Two Sigma Investments LP bought a new position in Quince Therapeutics in the 4th quarter worth about $57,000. Geode Capital Management LLC raised its position in Quince Therapeutics by 10.9% in the 4th quarter. Geode Capital Management LLC now owns 375,932 shares of the company's stock worth $703,000 after buying an additional 36,807 shares during the last quarter. Finally, Intellectus Partners LLC purchased a new stake in shares of Quince Therapeutics during the 1st quarter valued at about $71,000. Institutional investors own 30.75% of the company's stock.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.